Mesenchymal stem cell origin contributes to the antitumor effect of oncolytic virus carriers
Open Access
- 18 October 2024
- journal article
- research article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 32 (4) , 200896
Abstract
No abstract availableKeywords
Funding Information
- Vehicle Games Public Utility Foundation Memorial Foundation
- Japan Society for the Promotion of Science
This publication has 98 references indexed in Scilit:
- Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular CarcinomaMolecular Therapy, 2010
- Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cellsCancer Gene Therapy, 2007
- Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2Journal of Cellular Biochemistry, 2007
- Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virusMicrobes and Infection, 2007
- A potential role of somatostatin and its receptor SSTR4 in the migration of hepatic oval cellsLaboratory Investigation, 2006
- A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrowBlood, 2004
- Somatostatin is a selective chemoattractant for primitive (CD34+) hematopoietic progenitor cellsExperimental Hematology, 2002
- Stage-specific control of neuronal migration by somatostatinNature, 2002
- Somatostatin induces migration of acute myeloid leukemia cells via activation of somatostatin receptor subtype 2Leukemia, 2001
- Somatostatin receptors in the haematopoietic systemEuropean Journal of Endocrinology, 2000